In the human body, copper is an important trace element and is a cofactor for several important enzymes involved in energy production, iron metabolism, neuropeptide activation, connective tissue synthesis, and neurotransmitter synthesis. Copper is also necessary for cellular processes, such as the regulation of intracellular signal transduction, catecholamine balance, myelination of neurons, and efficient synaptic transmission in the central nervous system. Copper is naturally present in some foods and is available as a dietary supplement. Only small amounts of copper are typically stored in the body and a large amount of copper is excreted through bile and urine. Given the critical role of copper in a breadth of cellular processes, local concentrations of copper and the cellular distribution of copper transporter proteins in the brain are important to maintain the steady state of the internal environment. The dysfunction of copper metabolism or regulatory pathways results in an imbalance in copper homeostasis in the brain, which can lead to a myriad of acute and chronic pathological effects on neurological function. It suggests a unique mechanism linking copper homeostasis and neuronal activation within the central nervous system. This article explores the relationship between impaired copper homeostasis and neuropathophysiological progress in brain diseases.

Traumatic brain injury (TBI) induces complex secondary neuronal death, yet no specific therapeutic strategies are available to ameliorate post-traumatic neurological dysfunction. PANoptosis is a coordinated cell death pathway involving apoptosis, pyroptosis, and necroptosis; however, it remains unknown whether PANoptosis contributes to mild TBI (mTBI)-induced neuronal death and what precise mechanisms govern this process. This study aimed to investigate whether Snapin regulates neuronal PANoptosis following mTBI and to elucidate its functional mechanism through the hydrogen sulfide (H₂S)/ cathepsin D (CTSD) pathway. We utilized a controlled cortical impact (CCI) protocol to create a model of mTBI. Neuronal Snapin was conditionally knocked down via AAV-shSnapin. PANoptosis-related proteins were evaluated using immunofluorescence staining and Western blot. Endogenous H₂S levels were measured with a sulfide ion-selective electrode. The interaction between Snapin and cystathionine β-synthase (CBS) was examined by molecular docking and co-immunoprecipitation, while S-sulfhydration of CTSD was detected using a modified biotin switch assay. Therapeutic effects were assessed through behavioral tests including the wire-grip test, open field test, beam balanced walk, novel object recognition, and Morris water maze. Snapin was significantly upregulated in cortical and hippocampal neurons after mTBI. Knockdown of Snapin attenuated neurodegeneration, reduced PANoptosis-related proteins, and improved neurofunctional recovery. Mechanistically, Snapin bound to CBS, disrupting H₂S metabolic homeostasis and reducing endogenous H₂S levels. The decrease in H₂S limited S-sulfhydration of pro-CTSD, promoting its maturation into active CTSD and ultimately inducing PANoptosis. Both pepstatin A and NaHS treatment conferred neuroprotection, reducing neuronal death and neuroinflammation. Snapin promotes mTBI-induced neuronal PANoptosis by disrupting the H₂S/CTSD pathway through specific binding with CBS. Therapeutic strategies targeting Snapin, restoring H₂S homeostasis, or inhibiting CTSD activation may significantly alleviate neurological impairment and neuroinflammation post-mTBI, highlighting novel therapeutic avenues for mTBI treatment.